Brexanolone for postpartum depression
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
PURPOSE Postpartum depression (PPD) is defined as a major depressive episode occurring during pregnancy or within 4 weeks of delivery that may have significant consequences for mother and infant. Antidepressants are used to treat PPD, but their effectiveness may be limited by a slow time to peak effect. Brexanolone is Food and Drug Administration-approved for the management of PPD; its use requires patient participation in a risk evaluation and mitigation strategies (REMS) program. This review evaluates the efficacy and safety of brexanolone in PPD. SUMMARY Four completed studies, 1 quasi-experimental study and 3 randomized controlled trials (RCTs), were reviewed. Females who had moderate or severe PPD during the third trimester or within 4 weeks of delivery and were less than 6 months postpartum at initiation of therapy were included. Improvement in Hamilton Rating Scale for Depression (HAM-D) scores was assessed in addition to safety outcomes and scores on other depression rating scales. All studies demonstrated statistical improvement in HAM-D scores from baseline with brexanolone vs placebo use at the end of infusions (ie, hour 60). Results with regard to sustained HAM-D score improvements were mixed in the RCTs at 30-day follow-up. The most frequent adverse events in brexanolone-treated patients were sedation, dizziness, somnolence, and headache. The severe or serious adverse effect of presyncope, syncope, or loss of consciousness was reported by 4% of participants. CONC…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“According to Hutcherson and colleagues, only one of the two completed phase III RCTs provided evidence of remission beyond 30 days, and, in both, results were clouded by large placebo effects, narrow population samples, and other sources of bias [183,184].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [184]
In the citing paper
“However, a recent meta-analysis found less decisive conclusions [184].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [184]
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
Detection of Postnatal Depression: Development of the 10-item Edinburgh Postnatal Depression Scale
Cox, J. L., Holden, J. M., & Sagovsky, R. (1987) · British Journal of Psychiatry · doi:10.1192/bjp.150.6.782 · Cited by 14,183
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
(1976) · Medical Entomology and Zoology · Cited by 8,899
Perinatal Depression: A Systematic Review of Prevalence and Incidence
Gavin, N. I., Gaynes, B. N., Lohr, K. N., Meltzer-Brody, S., Gartlehner, G., & Swinson, T. (2005) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000183597.31630.db · Cited by 3,282
ECDEU Assessment Manual: (591322011-001)
Guy, W. (1976) · PsycEXTRA Dataset · doi:10.1037/e591322011-001 · Cited by 1,896
PRACTICE GUIDELINE FOR THE Treatment of Patients With Major Depressive Disorder
Gelenberg, A. J., Freeman, P. B., Markowitz, J. C., Rosenbaum, J. F., Thase, M. E., Trivedi, M. H., & Rhoads, R. S. (2010) · Cited by 1,510
Three-Year Outcomes for Maintenance Therapies in Recurrent Depression
Frank, E. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810240013002 · Cited by 1,297
Severity classification on the Hamilton depression rating scale
Zimmerman, M., Martinez, J. H., Young, D., Chelminski, I., & Dalrymple, K. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.04.028 · Cited by 1,199
Research works printed but not linked: 3
- 2018, Obstet Gynecol., e208
- Fitelson, 2011, Treatment of postpartum depression: clinical, psychological and pharmacological options, Int J Womens Health., 3, 1
- Zulresso [monograph]
Cited by
Khamidullina, Z., Marat, A., Muratbekova, S., Mustapayeva, N. M., Chingayeva, G. N., Shepetov, A. M., Ibatova, S. S., Terzic, M., & Aimagambetova, G. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14072418 · Cited by 63
“It is an intravenous medication approved for the treatment of PPD [114,116].”
Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression
Vecera, C. M., C. Courtes, A., Jones, G., Soares, J. C., & Machado-Vieira, R. (2023) · Pharmaceuticals · doi:10.3390/ph16111572 · Cited by 48
“However, a recent meta-analysis found less decisive conclusions [184].”
BackgroundResultReddy, D. S. (2021) · Journal of Neuroendocrinology · doi:10.1111/jne.13028 · Cited by 47
Zuranolone – synthetic neurosteroid in treatment of mental disorders: narrative review
Marecki, R., Kałuska, J., Kolanek, A., Hakało, D., & Waszkiewicz, N. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1298359 · Cited by 39
“It also exhibits very promising effects in the treatment of conditions outside the PPDs group (2–4).”
BackgroundInfluentialPillai, L., Srivastava, S., Ajin, A., Rana, S. S., Mathkor, D. M., Haque, S., Tambuwala, M. M., & Ahmad, F. (2023) · Journal of Psychosomatic Obstetrics & Gynecology · doi:10.1080/0167482x.2023.2278016 · Cited by 20
“Another pharmacotherapeutic agent recommended for PPD is the rapidly acting antidepressant brexanolone [57], although clinical studies have questioned its side-effects and safety.”
Background
Metadata
- Authors
- Hutcherson, T. C., Cieri-Hutcherson, N. E., & Gosciak, M. F.
- Affiliations
- D'Youville University (US)
- University at Buffalo School of Pharmacy and Pharmaceutical Science, Buffalo, NY
- Corresponding author
- Hutcherson, Timothy C
- Venue
- American Journal of Health-System Pharmacy
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-02-19
- Volume
- 77
- Issue
- 5
- Pages
- 336-345
- ISSN
- 1079-2082 (ISSN-L)
- 1535-2900
- OpenAlex
- W3007171661
- Cited by
- 25
- References
- 40
- Citations by year
- 2026: 6 · 2025: 8 · 2024: 1 · 2023: 6 · 2021: 3 · 2020: 1
- FWCI
- 0.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- American Journal of Health-System Pharmacy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Maternal Mental Health During Pregnancy and Postpartum
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Keywords
- brexanolone, postpartum depression, intravenous fluid therapy, rapid onset of action, risk evaluation and mitigation strategy, adverse events, syncope, sedation, antidepressant efficacy, maternal mental health
- MeSH terms
- Risk Evaluation and Mitigation, Antidepressive Agents, Drug Combinations, Female, Humans, Pregnancy, Pregnanolone, Psychiatric Status Rating Scales, Severity of Illness Index, Randomized Controlled Trials as Topic, Depression, Postpartum, beta-Cyclodextrins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Brexanolone for postpartum depression. https://app.cochat.ai/papers/10.1093/ajhp/zxz333
- The paper
- Hutcherson, T. C., Cieri-Hutcherson, N. E., & Gosciak, M. F. (2020). Brexanolone for postpartum depression. American Journal of Health-System Pharmacy. https://doi.org/10.1093/ajhp/zxz333
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.